Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157709505> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W3157709505 abstract "Abstract Background: Mitotane is a well-known adrenocytolitic agent resulting in adrenal insufficiency. However, little is known about its multiple and complex metabolic and endocrine effects. Clinical Case: Patient is a 6 year 9 month old female who presented with acne, pubic hair and rapid weight gain. Initial evaluation showed elevated testosterone (64 ng/dL), 17-OH-progesterone (236 ng/dL), DHEA-S (922 mcg/dL), and random cortisol (30.9 mcg/dL) with suppressed ACTH (<2.0 pg/mL). She had an inappropriate lack of suppression after a 1 mg overnight dexamethasone suppression test (cortisol 49 mcg/dL, nl <2 mcg/dL). Abdominal CT showed large necrotic-appearing right adrenal mass (10.7x8.8x15 cm) with no metastasis. Surgical excision was complicated by intraoperative rupture. Pathology confirmed stage III right adrenal cortical carcinoma. Patient was started on etoposide, cisplatin, doxorubicin, and mitotane as adjuvant therapy. 6 days after surgery, her DHEA-S and cortisol levels were undetectable. She was started on glucocorticoid replacement therapy with hydrocortisone at 18 mg/m2/day. Due to severe nausea, she was switched to dexamethasone 5 mg/m2/day (245 mg/m2/day dose equivalent to hydrocortisone). However, the patient developed hypotension, increased nausea and emesis and was switched back to hydrocortisone. The patient’s clinical course was complicated by hyperlipidemia with total cholesterol 215 mg/dL, HDL 48 mg/dL and LDL 150 mg/dL, as well as central hypothyroidism with low FT4 (0.8 ng/dL) and an inappropriately low normal TSH (0.31 mcIU/mL). She was started on levothyroxine with a final dose of 2.6mcg/kg/day to achieve euthyroid state. Mineralocorticoid deficiency has been reported in a small number of case reports of mitotane use. Our patient continues to demonstrate adequate mineralocorticoid function based on her normal electrolytes, aldosterone and plasma renin activity level. Conclusion: Mitotane exerts multiple clinically relevant metabolic and endocrine effects. Patients treated with mitotane should be monitored for complications including mineralocorticoid deficiency, central hypothyroidism, and hyperlipidemia. Dexamethasone must be avoided because of the rapid inactivation by CYP4503A4 leading to adrenal crisis. Typical glucocorticoid replacement dose must be doubled due to induction of CYP3A4 activity that leads to glucocorticoid inactivation." @default.
- W3157709505 created "2021-05-10" @default.
- W3157709505 creator A5001742238 @default.
- W3157709505 creator A5065220213 @default.
- W3157709505 creator A5069557132 @default.
- W3157709505 date "2021-05-01" @default.
- W3157709505 modified "2023-09-24" @default.
- W3157709505 title "Mitotane in the Treatment of Adrenocortical Carcinoma: Metabolic and Endocrine Disruption" @default.
- W3157709505 doi "https://doi.org/10.1210/jendso/bvab048.1430" @default.
- W3157709505 hasPublicationYear "2021" @default.
- W3157709505 type Work @default.
- W3157709505 sameAs 3157709505 @default.
- W3157709505 citedByCount "0" @default.
- W3157709505 crossrefType "journal-article" @default.
- W3157709505 hasAuthorship W3157709505A5001742238 @default.
- W3157709505 hasAuthorship W3157709505A5065220213 @default.
- W3157709505 hasAuthorship W3157709505A5069557132 @default.
- W3157709505 hasBestOaLocation W31577095051 @default.
- W3157709505 hasConcept C126322002 @default.
- W3157709505 hasConcept C134018914 @default.
- W3157709505 hasConcept C2776694085 @default.
- W3157709505 hasConcept C2776735609 @default.
- W3157709505 hasConcept C2777977426 @default.
- W3157709505 hasConcept C2778119113 @default.
- W3157709505 hasConcept C2778129406 @default.
- W3157709505 hasConcept C2778709874 @default.
- W3157709505 hasConcept C2780401358 @default.
- W3157709505 hasConcept C2780455818 @default.
- W3157709505 hasConcept C2780580376 @default.
- W3157709505 hasConcept C2781399356 @default.
- W3157709505 hasConcept C46699223 @default.
- W3157709505 hasConcept C71315377 @default.
- W3157709505 hasConcept C71924100 @default.
- W3157709505 hasConcept C90924648 @default.
- W3157709505 hasConceptScore W3157709505C126322002 @default.
- W3157709505 hasConceptScore W3157709505C134018914 @default.
- W3157709505 hasConceptScore W3157709505C2776694085 @default.
- W3157709505 hasConceptScore W3157709505C2776735609 @default.
- W3157709505 hasConceptScore W3157709505C2777977426 @default.
- W3157709505 hasConceptScore W3157709505C2778119113 @default.
- W3157709505 hasConceptScore W3157709505C2778129406 @default.
- W3157709505 hasConceptScore W3157709505C2778709874 @default.
- W3157709505 hasConceptScore W3157709505C2780401358 @default.
- W3157709505 hasConceptScore W3157709505C2780455818 @default.
- W3157709505 hasConceptScore W3157709505C2780580376 @default.
- W3157709505 hasConceptScore W3157709505C2781399356 @default.
- W3157709505 hasConceptScore W3157709505C46699223 @default.
- W3157709505 hasConceptScore W3157709505C71315377 @default.
- W3157709505 hasConceptScore W3157709505C71924100 @default.
- W3157709505 hasConceptScore W3157709505C90924648 @default.
- W3157709505 hasLocation W31577095051 @default.
- W3157709505 hasOpenAccess W3157709505 @default.
- W3157709505 hasPrimaryLocation W31577095051 @default.
- W3157709505 hasRelatedWork W10354902 @default.
- W3157709505 hasRelatedWork W11097087 @default.
- W3157709505 hasRelatedWork W12844489 @default.
- W3157709505 hasRelatedWork W15400452 @default.
- W3157709505 hasRelatedWork W1588409 @default.
- W3157709505 hasRelatedWork W16297051 @default.
- W3157709505 hasRelatedWork W3348734 @default.
- W3157709505 hasRelatedWork W6731183 @default.
- W3157709505 hasRelatedWork W6800933 @default.
- W3157709505 hasRelatedWork W6870719 @default.
- W3157709505 isParatext "false" @default.
- W3157709505 isRetracted "false" @default.
- W3157709505 magId "3157709505" @default.
- W3157709505 workType "article" @default.